Pasithea Therapeutics Statistics
Share Statistics
Pasithea Therapeutics has 2.71M
shares outstanding. The number of shares has increased by 159.31%
in one year.
| Shares Outstanding | 2.71M |
| Shares Change (YoY) | 159.31% |
| Shares Change (QoQ) | 113.61% |
| Owned by Institutions (%) | 0.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 212,519 |
| FTD / Avg. Volume | 7.5% |
Short Selling Information
The latest short interest is 416.94K, so 15.41% of the outstanding
shares have been sold short.
| Short Interest | 416.94K |
| Short % of Shares Out | 15.41% |
| Short % of Float | 16.77% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Pasithea Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.58,
with a Debt / Equity ratio of 0.
| Current Ratio | 6.58 |
| Quick Ratio | 6.58 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-3,476,146,000 |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -78.18% in the
last 52 weeks. The beta is 0.59, so Pasithea Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.59 |
| 52-Week Price Change | -78.18% |
| 50-Day Moving Average | 1.3 |
| 200-Day Moving Average | 3.13 |
| Relative Strength Index (RSI) | 52.72 |
| Average Volume (20 Days) | 2,835,291 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.25B |
| Net Income | -13.9B |
| EBITDA | -13.26M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -12685.72 |
Full Income StatementBalance Sheet
The company has 6.92M in cash and 0 in
debt, giving a net cash position of 6.92M.
| Cash & Cash Equivalents | 6.92M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -49.58B |
| Total Assets | 16.06M |
| Working Capital | 6.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -13.92B
and capital expenditures 0, giving a free cash flow of -13.92B.
| Operating Cash Flow | -13.92B |
| Capital Expenditures | n/a |
| Free Cash Flow | -13.92B |
| FCF Per Share | -12702.92 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
